Page 2 - Protein Sciences News Today

Bio-Techne Corporation beats earnings expectations. Reported EPS is $0.48, expectations were $0.46.

/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2024. Third Quarter FY2024...

MINNEAPOLIS, April 26, 2024 /PRNewswire/ -- Bio-Techne Corporation and Novomol-Dx, a molecular diagnostics company, are pleased to announce the development of Bio-Marker Pathfinder , a first of...

/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 1, 2024, at...

Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) and Bio-Techne (NASDAQ:TECH – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, dividends, risk and institutional ownership. Analyst Recommendations This is a breakdown of current ratings […]

MINNEAPOLIS, Feb. 1, 2024 /PRNewswire/ -- Bio-Techne Corporation today reported its financial results for the second quarter ended December 31, 2023. Second Quarter FY2024 Highlights Second quarter...

Organic Revenue Declines as Company Navigates Macroeconomic Challenges

MINNEAPOLIS, Jan. 24, 2024 /PRNewswire/ -- Bio-Techne Corporation had the honor of welcoming presentations from leading scientists from two major biopharmaceutical companies, Pfizer and Sanofi, at...

INTEGRA Biosciences has awarded 50 EVOLVE manual pipettes, GRIPTIPS® pipette tips worth US $1000 and various lab accessories to UK-based start-up Creasallis, helping to accelerate its pioneering research into improving the penetration of therapeutic antibodies into tumors. Click to read more...

Bio-Techne (NASDAQ:TECH – Get Free Report) and Genfit (NASDAQ:GNFT – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Analyst Ratings This is a summary of current ratings and […]